Phase II study of rituximab in the treatment of cladribine-failed patients (pts.) with hairy cell leukemia (HCL).

被引：0
|
作者：
Nieva, J
Bethel, K
Baker, T
Saven, A
机构：
[1] Scripps Res Inst, Dept Pathol, La Jolla, CA USA
[2] Scripps Canc Ctr, La Jolla, CA USA
[3] Cecil H & Ida M Green Canc Ctr, La Jolla, CA USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1535
引用
收藏
页码：364A / 365A
页数：2
相关论文
共 50 条
  • [1] Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia
    Nieva, J
    Bethel, K
    Saven, A
    BLOOD, 2003, 102 (03) : 810 - 813
  • [2] RITUXIMAB IN COMBINATION WITH CLADRIBINE IN HAIRY CELL LEUKEMIA (HCL)
    Basic-Kinda, S.
    Dujmovic, D.
    Roncevic, P.
    Radman, I.
    Dotlic, S.
    Kuvezdic, K.
    Dubravcic, K.
    Aurer, I.
    HAEMATOLOGICA, 2013, 98 : 547 - 547
  • [3] Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia
    Ravandi, Farhad
    O'Brien, Susan
    Jorgensen, Jeffrey
    Pierce, Sherry
    Faderl, Stefan
    Ferrajoli, Alessandra
    Koller, Charles
    Challagundla, Pramoda
    York, Sergernne
    Brandt, Mark
    Luthra, Rajyalakshmi
    Burger, Jan
    Thomas, Deborah
    Keating, Michael
    Kantarjian, Hagop
    BLOOD, 2011, 118 (14) : 3818 - 3823
  • [4] Phase II Clinical Study of Cladribine in the Treatment of Hairy Cell Leukemia
    Takashi Machii
    Takaaki Chou
    Muneou Suzuki
    Yokiko Ohe
    Shuichi Katagiri
    Katagiri Kitano
    Yoshihide Fujiyama
    Tooru Izumi
    Chihiro Shimazaki
    Koji Nanba
    Yasuo Ohashi
    Teruo Kitani
    International Journal of Hematology, 2005, 82 : 230 - 235
  • [5] Phase II clinical study of cladribine in the treatment of hairy cell leukemia
    Machii, T
    Chou, T
    Suzuki, M
    Ohe, Y
    Katagiri, S
    Kitano, K
    Fujiyama, Y
    Izumi, T
    Shimazaki, C
    Nanba, K
    Ohashi, Y
    Kitani, T
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 82 (03) : 230 - 235
  • [6] Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia
    Kreitman, Robert J.
    Wilson, Wyndham
    Calvo, Katherine R.
    Arons, Evgeny
    Roth, Laura
    Sapolsky, Jeffrey
    Zhou, Hong
    Raffeld, Mark
    Stetler-Stevenson, Maryalice
    CLINICAL CANCER RESEARCH, 2013, 19 (24) : 6873 - 6881
  • [7] Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.
    Chihara, Dai
    Arons, Evgeny
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Zhou, Hong
    Raffeld, Mark
    Xi, Liqiang
    Steinberg, Seth M.
    Wisch, Laura
    Feurtado, Julie
    James-Echenique, Lacey
    Braylan, Raul
    Calvo, Katherine R.
    Maric, Irina
    Dulau, Alina
    Kreitman, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia
    Ravandi, Farhad
    Jorgensen, Jeffrey
    O'Brien, Susan
    Thomas, Deborah A.
    Faderl, Stefan
    York, Sergernne
    Burger, Jan A.
    Ferrajoli, Alessandra
    Pierce, Sherry
    Keating, Michael
    Kantarjian, Hagop
    BLOOD, 2010, 116 (21) : 1020 - 1021
  • [9] Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia
    Chihara, Dai
    Arons, Evgeny
    Stetler-Stevenson, Maryalice
    Yuan, Constance M.
    Wang, Hao-Wei
    Zhou, Hong
    Raffeld, Mark
    Xi, Liqiang
    Steinberg, Seth M.
    Feurtado, Julie
    James, Lacey
    Wilson, Wyndham
    Braylan, Raul C.
    Calvo, Katherine R.
    Maric, Irina
    Dulau-Florea, Alina
    Kreitman, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) : 1527 - +
  • [10] Phase II study of cladribine (2CDA) followed by rituximab for eradication of minimal residual disease (MRD) in hairy cell leukemia (HCL).
    Ravandi-Kashani, F
    Kantarjian, H
    Verstovsek, S
    Koller, C
    Faderl, S
    Thomas, D
    Jones, D
    Jorgensen, J
    O'Brien, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 590S - 590S
12345